University of Pennsylvania Engineers Develop Universal Nanoparticle Therapy to Reinvigorate Exhausted T Cells in Solid Tumors

New pLNP therapy from UPenn combines IDO inhibition and mRNA delivery to eliminate solid tumors and build lasting immune memory in pre-clinical trials.

By: AXL Media

Published: Mar 18, 2026, 8:15 AM EDT

Source: Information for this report was sourced from University of Pennsylvania School of Engineering and Applied Science

Addressing the Bottleneck of T Cell Exhaustion

A primary obstacle in the treatment of solid tumors—such as breast, liver, and colon cancers—is the rapid exhaustion of the body’s natural immune response. Within the hostile environment of a tumor, white blood cells known as T cells are deprived of nutrients and bombarded with suppressive signals, eventually losing their ability to destroy malignant cells. To counter this, engineers at the University of Pennsylvania have developed a universal immunotherapy that seeks to "refuel" these cells while simultaneously releasing the molecular "brakes" that hinder their activity.

Engineering the Dual Function Prodrug Nanoparticle

The research team, led by Associate Professor Michael J. Mitchell, moved beyond traditional delivery vehicles by chemically linking an IDO-blocking drug directly to the ionizable lipid of the nanoparticle. This creates a "prodrug" lipid nanoparticle, or pLNP, where the vehicle itself is an active part of the therapy. By integrating the drug into the lipid structure, the system ensures the simultaneous delivery of the IDO inhibitor alongside mRNA instructions that prompt tumor cells to produce interleukin-12 (IL-12), a potent immune-stimulating protein.

Transforming Cold Tumors into Immune Hotzones

Pre-clinical testing in animal models has demonstrated that this integrated approach is significantly more effective than delivering the two components separately. In mice with established colon cancer, the pLNPs nearly eliminated tumors within 30 days while increasing the presence of "killer" T cells. The therapy successfully transformed "cold" tumors, which typically evade the immune system, into "hot," inflamed environments rich in immune activity. Notably, the treated subjects showed lower levels of PD-1, a primary biological marker associated with T cell exhaustion.